"Factors May Help Predict Which Patients with HER2-Positive Breast Cancer Can Forgo Surgery" - John DeRosier
Physicians may be able to predict which patients with HER2-positive breast cancer can safely forgo surgery based on tumor hormone status, imaging results after neoadjuvant chemotherapy and ductal carcinoma in situ on initial biopsy, according to study results presented at the American Society of Breast Surgeons Annual Meeting. “This is an exciting concept and there’s an ongoing NRG cooperative group trial in the United States and Canada addressing this issue, seeking to identify exceptional responders to neoadjuvant chemotherapy and define which patients may not benefit from surgery after treatment,” said Hank Schmidt, MD, PhD, associate professor of surgery at the Icahn School of Medicine at Mount Sinai. “Such an approach could one day allow patients to avoid surgery that can have long-term cosmetic implications, which would be an advantage for these patients in terms of quality of life.”
— Hank Schmidt, MD, PhD, Associate Professor, Surgery, Icahn School of Medicine at Mount Sinai
